2-Me-DMT Stats & Data

Harm-reduction additions and rationale are provided above this JSON. Summary of key points: human data for 2-Me-DMT are very sparse; dosing/duration primarily come from TIHKAL and scattered reports, so conservative titration and allergy tests are essential. Oral onset can be delayed beyond an hour; redosing early risks accidental over-intoxication. MAOIs (including moclobemide and plant harmalas) can dramatically potentiate tryptamines; avoid unless following specific, well-researched ayahuasca protocols due to hypertensive/serotonergic risks. Tramadol is both serotonergic and lowers seizure threshold and is best avoided with psychedelics. Auditory pitch-shifting and other timbre/pitch distortions have been repeatedly described for 2-position–substituted tryptamines, including 2-Me-DMT, and may be prominent at moderate doses. Vaporizing requires technique: use indirect heat and screens to vaporize rather than burn; harsh hot vapor can irritate lungs and make dosing erratic. Insufflation may damage nasal mucosa; if used, keep doses low, avoid frequent re-dosing, and rinse with saline. As with classic psychedelics, short-term tolerance builds rapidly and cross-tolerance with other serotonergic psychedelics is expected; spacing sessions by at least a week is prudent. Psychedelic crises can occur; a sober sitter, calm environment, and access to a benzodiazepine rescue dose (from a legitimate prescription) can help, though benzos carry their own risks. HPPD-like persistent visual phenomena are rare but documented with serotonergic psychedelics generally; those with personal/family histories of psychosis should be particularly cautious. Use reagent testing to confirm an indole and rule out dangerous mis-sold compounds; multiple reagents and, ideally, lab testing provide the best assurance.